Knowledge of the mode of action and metabolism of vitamin D has made rapid progress in the past few years. The discovery that ingested vitamin D undergoes transformation to a circulating metabolite, that this metabolite then undergoes further transformation into a more biologically active form, and that production of these metabolites may be subject to feedback control mechanisms, has led to the recognition that 'vitamin D' could be regarded as a hormone as well as a vitamin. This hormonal concept of the antirickets agent is far from new, however, for in 1919, the same year that Mellanby discovered that cod liver oil could cure rickets, Huldschinsky (quoted by Loomis, 1970) showed that ultraviolet irradiation of a single limb would cure rickets not only in the irradiated limb but in the other limbs as well; these findings had thus already fulfilled the criteria of a hormone as a substance synthesized at one site in the body and exerting a powerful metabolic effect at a site distant from the point of synthesis. The nature of this effect has now become clearer, and the purpose of the present review is to trace the most recent developments in this field and their bearing on problems in clinical medicine.
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Much of our knowledge of the physiology of vitamin D is summarized in Fig 1. Cholecalciferol (vitamin D3) and possibly other antirachitic compounds are formed in the skin by the action of ultraviolet irradiation on the physiological precursor 7-dehydrocholesterol. 7-Dehydrocholesterol synthesis is active in both liver and skin (Gaylor and Sault, 1964) , but the exact way in which its irradiation products are absorbed through the skin in man is uncertain. Early studies (Helmer and Jansen, 1937a, b) showed that antirachitic material was recoverable from human skin washings and that cholecalciferol could cure rickets when applied to unbroken animal skin. More recently Gaylor and Sault (1964) Wheatley and Reinertson (1958) suggested that 7-dehydrocholesterol was maximally concentrated in the malpighian layer of human skin and that very little was present in the dermis where the sebaceous glands arise. Furthermore, Thomson (1955) showed that a large proportion of ultraviolet light of wavelength which included the antirachitic range (290-320 m ±) could readily penetrate the stratum corneum of Caucasian skin (Loomis, 1967) . There may thus be no need to postulate that 7-dehydrocholesterol must first reach the skin surface before effective irradiation occurs, as in fur-bearing animals. While further work on skin synthesis and absorption of cholecalciferol is required, it is almost certain that dietary sources of vitamin D are only required when a man is shielded from effective sunshine by clothing, housing conditions, or industrial smog.
Apart from certain oily fish which contain large quantities of cholecalciferol (which they synthesize for reasons which are at present obscure), natural animal products are surprisingly deficient in vitamin D considering the natural connotations of the word 'vitamin'. Fig. 1 shows vitamin D3 (and calcium salts) from natural dietary sources entering the small intestine. Vitamin D3 is absorbed throughout the small intestine in humans, though the site of maximal absorption is still uncertain (Arnstein, Frame, and Frost, 1967) . Bile salts appear absolutely necessary for its absorption in micelle form (Schachter, Finkelstein, and Kowarski, 1964; Avioli, 1969) , and hepatic osteomalacia due to biliary obstruction can be cured by parenteral administration of physiological amounts of cholecalciferol (Dent and Stamp, 1970) . Nevertheless, osteomalacia remains an uncommon complication of long-standing liver disease, and osteoporosis alone is much more commonly seen (Atkinson, Nordin, and Sherlock, 1956) . Almost any form of steatorrhoea may be complicated by rickets or osteomalacia, and when it is due to gluten-sensitive enteropathy the rickets may be resistant even to quite large doses of vitamin D injected parenterally (Nassim et al., 1959) . This is considered further below. The osteomalacia which may follow partial gastrectomy may not infrequently be due to selfrestriction of vitamin D-containing fatty foods (Thompson, Lewis, and Booth, 1966) .
Major advances in our understanding of vitamin D metabolism have followed the use of isotopically labelled cholecalciferol. The first studies in this field were performed by Kodicek (1955) but it was not until 11 years later that Neville and DeLuca (1966) and Callow, Kodicek, and were able to synthesize an isotope of high enough specific activity (20,000-26,000 DPM/IU) to clarify the pathways of vitamin D metabolism. After administration of the isotope to intact animals, chromatographic techniques were used to separate further discrete peaks of radioactivity corresponding to hydroxylated, and therefore more polar, metabolites of the parent vitamin. It was then shown that the major circulating form of the vitamin was a compound in which a second hydroxyl group had been introduced, and this was identified by DeLuca and his coworkers (DeLuca, 1969) as 25-hydroxycholecalciferol (25-HCC, Fig. 2 ). It was shown that synthesis of 25-HCC could be accomplished only by liver (Ponchon and DeLuca, 1969) , and more recently this synthesis has been shown to be product-inhibited (DeLuca, 1971) . There is also an enterohepatic recirculation of vitamin D and its metabolites, largely conjugated as glucuronides before secretion into the bile (Avioli et al., 1967) , and bile fistulae may thus lead to vitamin D depletion. Earlier studies by Zull, Czarnowska-Misztal, and DeLuca (1966) had shown that after oral administration of cholecalciferol to rachitic rats there was a 16-to 20-hour delay before increased calcium uptake by subsequently-removed small intestine could be shown in vitro. This time lag was reduced to about 6 hours when 25-HCC instead of cholecalciferol was administered, but the continuing, though smaller, time lag suggested that further metabolism to a compound with immediate biological activity might be required. Lawson, Wilson, and Kodicek (1969) had detected a previously undescribed metabolite in isolated chick intestinal cell nuclei, and it was further discovered that this metabolite could be synthesized only by kidney (Fraser and Kodicek, 1970) . This metabolite, identified as 1,25-dihydroxycholecalciferol (Fig. 2, 1 ,25-DHCC) by Lawson et al. (1971) , was found to have a powerful action in promoting intestinal calcium absorption (Kodicek, Lawson, and Wilson, 1970) . Its structure and immediate powerful effect have been amply confirmed (Holick, Schnoes, and DeLuca, 1971; Haussler et al., 1971; Myrtle and Norman, 1971; Wong and Norman, 1972) , and 1,25-DHCC is now regarded as the active, hormonal form ofthe vitamin. Other polar metabolites of cholecalciferol have also been isolated, including 25,26-dihydroxycholecalciferol with some action on intestine but none on bone, and one, whose characterization has become uncertain, which has some action on bone but little on intestine (Suda et al., 1970b, a (Boyle, Gray, and DeLuca, 1971) . Thus low calcium intake and associated hypocalcaemia in vitamin D-deficient rats resulted in the rapid accumulation of 1,25-DHCC in the intestine and other organs. As dietary, and therefore plasma, calcium levels were raised, the accumulation of 1,25-DHCC decreased while the proportion of the second metabolite rose (Omdahl et al., 1972 (Rasmussen et al., 1972) , and corresponding changes in the responsible renal enzyme activity have also been shown (Fraser and Kodicek, 1973) .
Thus a further refinement in calcium homeostasis may be described in which parathyroid hormone secretion, responding to a fall in plasma calcium, not only influences bone calcium mobilization directly but also stimulates 1,25-DHCC synthesis. This in turn enhances both intestinal calcium absorption and bone calcium mobilization (see below), the process being reversed as plasma calcium rises. Synthesis of 1,25-DHCC by the kidney and its subsequent localization in the intestine is represented in Fig. 1 . Calcium is absorbed from the intestinal lumen and transported across the mucosal cell in association with calcium-binding protein (CaBP). The precise mechanism of CaBP production is also uncertain; DNA transcription into messenger RNA is required for the renal synthesis of 1,25-DHCC; actinomycin D, therefore, inhibits this step; the drug has been claimed, however, not to affect the formation of CaBP, under the influence of 1,25-DHCC, from a possible precursor protein in the intestine (Drescher and DeLuca, 1971; Corradino and Wasserman, 1972) , but evidence here is at present conflicting (D. E. M. Lawson, personal communication, 1972 (Reynolds, 1972) , while 1,25-DHCC was 100-fold times more active in this respect (Raisz et al., 1972) . However, in the experimental animal, nephrectomy completely prevents the bone calcium mobilization response to 25-HCC, but not to 1,25-DHCC (Holick, Garabedian, and DeLuca, 1972a Fig. 2 .
Synthesis of 1,25-DHCC in human kidney has been confirmed (D. R. Fraser, personal communication, 1971 ) and characteristic radioactivity corresponding to 1,25-DHCC has been detected in human plasma (Mawer et al., 1971a ; T. C. B. Stamp and D. E. M. Lawson, unpublished data), but not in a nephrectomized patient (Mawer et al., 1971a) . Its renal synthesis in rats has recently been localized to the tubule (Shain, 1972) . Failure of the renal synthesis of 1,25-DHCC thus provides the most logical explanation of much of the mystery of renal rickets, and of the early occurrence of rickets in patients with severe tubular failure but little glomerular failure as in the Lignac-Fanconi syndrome (cystinosis) with its early characteristic 'swan-neck' deformity of the proximal renal tubule. Atrophy of the jejunal mucosa with consequent failure of the 1,25-DHCC/calcium-binding protein system may provide part of the explanation for vitamin D resistance in gluten-sensitive enteropathy.
The liver of man and animals has long been considered as the major storage site of vitamin D, and indeed animal liver is the only meat product that contains significant amounts. Nevertheless, necropsy and amputation studies in patients who had received pharmacological amounts of vitamin D (Lumb, Mawer, and Stanbury, 1971) showed with bioassay techniques that skeletal muscle and adipose tissue may provide a large storage reservoir from which vitamin D may be slowly released as plasma levels fall. The form in which vitamin D is stored in this reservoir, whether as the parent vitamin or as 25-HCC, is uncertain, since chemical rather than bioassay analysis must be applied.
Various therapeutic trials of 25-HCC in pharmacological dosage have been reported in the sexlinked form of vitamin D-resistant rickets, in hypoparathyroidism, anticonvulsant osteomalacia, and in chronic renal failure, and recent evidence suggests that in some situations it may be several times more potent on a weight basis than the standard preparations of vitamin D2 or D3 in current use (Balsan and Garabedian, 1972; Stamp et al., 1972) . Further strides in this field have been made with the recent development of competitive protein-binding assays for 25-HCC, which have permitted its accurate chemical determination in human plasma (Belsey, DeLuca, and Potts, 1971; Haddad and Chyu, 1971) . Mean 25-HCC levels in both normal adults and adolescent schoolchildren in London were 16±1 (SEM) ng/ml (Stamp et al., 1972) . On an equivalence of 1 mg 25-HCC = 50,000 IU of vitamin D activity (DeLuca, 1971) , this corresponds to a figure of 0 -8 IU/ml; this same figure for normal subjects has been reported by Lumb et al. (1971) in Manchester, Thompson et al. (1967) in London, and Illig, Antener, and Prader (1961) in Switzerland using bioassay techniques. The possibility that circulating antirachitic activity may thus be composed largely if not entirely of 25-HCC in normal human plasma is consistent with studies using isotopically labelled cholecalciferol which showed the virtual disappearance of isotopically labelled D3 from the plasma within 2 to 5 days after injection (Mawer et al., 1971b) ; unpublished studies in our own laboratory have confirmed this. The actual rate of disappearance of isotopically labelled cholecalciferol and rate of appearance of 25-HCC and other more polar metabolites has been shown to depend upon pool size in individual patients, that is on their state of vitamin D nutrition (Mawer et al., 1971b) , rather than reflecting any abnormality of vitamin D metabolism as was first proposed by Avioli and his co-workers (Avioli et al., 1968) for patients with chronic renal failure.
25-hydroxylation of cholecalciferol and of ergocalciferol proceeds normally in patients with both sex-linked variety of hypophosphataemic rickets and the recessively-inherited vitamin D-dependency rickets (Haddad et al., 1973) . The occurrence of rickets and osteomalacia due to long-term anticonvulsant therapy in epilepsy (Kruse, 1968; Dent et al., 1970) was postulated to arise from hepatic enzyme induction leading to increased breakdown of vitamin D to inactive metabolites and thereby to increased vitamin D requirement in these patients. Confirmation of this theory has been assisted by the demonstration of abnormally low levels of 25-HCC in plasma from these patients (Stamp et al., 1972) and by the demonstration of phenobarbitone-induced alterations in vitamin D metabolism (Hahn et al., 1972) . Other forms of hereditary or acquired vitamin Dresistant rickets (Dent, 1970) may well result from abnormalities of vitamin D metabolism, and clinical scientists are now poised to explore and clarify many of these poorly understood conditions. Meanwhile, many old established clinicopharmacological phenomena are already clearer. The delayed action of vitamin D2, when given in large doses to heal metabolic rickets or to raise the plasma calcium in hypoparathyroidism, is clearly due to its required conversion to a more active form. This conversion may also be severely inhibited by the lack of parathyroid hormone. The rapid action of dihydrotachysterol (DHT, AT 10) in raising plasma calcium may result from its steric configuration which in some ways more closely resembles 1,25-DHCC (Fig. 2) . This resemblance could give it a rapid action on bone resorption in hypoparathyroidism and, in high dosage, on the CaBP system in various forms of resistant rickets. On the other hand the inadequate conversion of DHT to a true hormonal form of the vitamin, such as 1,25-DHCC or 1,25-dihydroxyergocalciferol, may explain its inadequacy in small dosage in the treatment of nutritional rickets.
Synthetic analogues of vitamin D3 and 25-HCC in which the A-ring has been rotated through 1800 so that it resembles the steric configuration of DHT in the position of the hydroxyl group (Fig. 2) have recently been found effective on bone and intestine in the absence of the kidneys, a situation where the natural compounds are without effect (Holick, Garabedian, and DeLuca, 1972b 
